8 research outputs found

    Influence of the initial cooling rate from γ′ supersolvus temperatures on microstructure and phase compositions in a nickel superalloy

    Get PDF
    Different cooling paths from a supersolvus temperature have been applied to FGH96, a polycrystalline nickel base superalloy for turbine disc applications, in order to simulate the different microstructures that exist through the thickness of a disc following an industrial heat treatment. Secondary and tertiary γ′ precipitate size distributions and morphology have been analysed and compared for the different heat treatments using SEM and atom probe tomography (APT). Detailed compositional data for both γ′ precipitate and γ matrix are presented, and compared to equilibrium compositions calculated by Thermo-Calc. For the heat-treatments studied, the secondary γ′ composition indicates a shell of differing composition to that towards the precipitate core. From sequential equilibria compositional calculations, it is suggested that the ‘shell’ forms at a lower temperature than the precipitate core. The fine tertiary precipitates do not show the core-shell compositional differences on continuous cooling. W peaks are noted at the γ/γ′ interfacial region, which is of significance for retarding coarsening. A γ′ depletion zone surrounds the secondary precipitates, within which the γ matrix composition differs significantly to the γ far-field values, Finally, a precipitate nucleation and growth mechanistic model is suggested based on the experimental data and Thermo-Calc calculations

    Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control:statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis

    Get PDF
    RATIONALE: Thrombolysis with intravenous alteplase is both effective and safe when administered to particular types of patient within 4·5 hours of having an ischemic stroke. However, the extent to which effects might vary in different types of patient is uncertain. AIMS AND DESIGN: We describe the protocol for an updated individual patient data meta-analysis of trials of intravenous alteplase, including results from the recently reported third International Stroke Trial, in which a wide range of patients enrolled up to six-hours after stroke onset were randomized to alteplase vs. control. STUDY OUTCOMES: This protocol will specify the primary outcome for efficacy, specified prior to knowledge of the results from the third International Stroke Trial, as the proportion of patients having a 'favorable' stroke outcome, defined by modified Rankin Score 0-1 at final follow-up at three- to six-months. The primary analysis will be to estimate the extent to which the known benefit of alteplase on modified Rankin Score 0-1 diminishes with treatment delay, and the extent to which it is independently modified by age and stroke severity. Key secondary outcomes include effect of alteplase on death within 90 days; analyses of modified Rankin Score using ordinal, rather than dichotomous, methods; and effects of alteplase on symptomatic intracranial hemorrhage, fatal intracranial hemorrhage, symptomatic ischemic brain edema and early edema, effacement and/or midline shift. DISCUSSION: This collaborative meta-analysis of individual participant data from all randomized trials of intravenous alteplase vs. control will demonstrate how the known benefits of alteplase on ischemic stroke outcome vary across different types of patient

    A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    Get PDF

    Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

    No full text
    The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918
    corecore